Nuclear fusion funding tracker (85 deals)

Our funding tracker covering the nuclear fusion market

Below is the table listing all the deals. You may find our methodology at the end of this page.

And, if you want to gain a deeper understanding of the market and its current dynamics, get our report covering the nuclear fusion market.

Is nuclear fusion actually a well-funded market today?

Nuclear fusion is attracting serious money today, but the $8.85 billion headline makes the market look broader than it really is.

Across the period we studied, 84 qualifying financings went to 53 companies. Only 67 deals disclosed a usable amount, yet those disclosed and approximated rounds already add up to at least $8.85 billion.

The more useful benchmark for a normal company is the median disclosed round: $33.8 million. The average is $132.1 million, almost four times higher, because several companies are raising sums that look closer to industrial-project financing than ordinary venture rounds.

Strip out every financing above $100 million and the total falls to about $1.38 billion. Remove rounds above $50 million and only around $616 million remains. These days, fusion really does have a multibillion-dollar funding market, but most of those billions sit with a fairly small group of companies building expensive integrated systems.

The broader sector is also having a strong year. The Fusion Industry Association reported that 56 companies raised $4.48 billion in the 12 months to July 2026, its highest annual figure since the survey began. Our market definition and inclusion rules differ, but the direction is the same: large private financing has accelerated sharply.

How many nuclear fusion companies are actually raising money?

The nuclear fusion funding market currently consists of 53 companies in our research, far fewer than the 84 financing announcements might suggest.

Thirty-four companies appear once during the period. Ten raise twice. Only nine raise three times or more.

A long stream of announcements can make fusion look like a huge collection of equally financeable startups. In practice, only 19 companies return for more than one financing during the window.

Those repeat raisers collect roughly $5.09 billion, compared with about $3.76 billion for the 34 companies that appear only once. Funding gets progressively pulled toward companies that can keep showing technical progress and come back for the next, usually larger, check.

Financings per company	Companies	Share of companies
1	34	64.2%
2	10	18.9%
3+	9	17.0%
More than one	19	35.8%
Total	53	100%

Is nuclear fusion funding concentrated in just a few companies?

Yes. Nuclear fusion funding is currently concentrated very heavily at the top, with five companies accounting for almost 64% of the capital we can quantify.

Commonwealth Fusion Systems alone raised $1.863 billion during the period. NeoFusion contributes about $1.31 billion, although that figure comes from a subscribed registered-capital increase and should be read carefully. Helion raised $925 million, Pacific Fusion announced more than $900 million, and Proxima Fusion accumulated $657.3 million.

The top ten companies together absorb about 83% of quantified capital.

Several of these companies also keep coming back. CFS raised $863 million in 2025 and another $1 billion in 2026. Helion had three financings in our window. Proxima had four. Startorus had four.

That repeat access to large checks is one of the clearest dividing lines in fusion today. Plenty of teams can raise enough to start developing a reactor concept. Far fewer can convince investors to finance the next machine, then the one after that.

Company	Financings	Capital recorded in the period
Commonwealth Fusion Systems	2	$1.863B
NeoFusion	1	$1.310B
Helion Energy	3	$925M
Pacific Fusion	1	>$900M
Proxima Fusion	4	$657.3M
Inertia Enterprises	1	$450M
Startorus Fusion	4	$387.5M
NovaFusionX	3	$350.1M+
Focused Energy	2	$251.7M
China Fusion Energy	1	$240.3M

What can a normal nuclear fusion startup expect to raise?

For most nuclear fusion startups, a financing in the tens of millions is much more normal than a nine-figure round.

The median disclosed financing is $33.8 million. Eight rounds are below $5 million, 19 fall between $5 million and $20 million, and another 12 sit between $20 million and $50 million.

Then the market changes character. Twenty-one quantified deals reach at least $100 million and together account for almost 88% of recorded capital.

Xcimer's $100 million Series A funded a new facility and prototype laser system. Thea Energy's $100 million Series B is going into magnet manufacturing and construction of an integrated fusion system. Focused Energy's $240 million Series A is designed to finance a much larger step toward a fusion power plant.

So a fusion company can start on venture-sized money. Once it begins building integrated hardware at meaningful scale, the check size can jump very quickly.

Round size	Deals	Share of all deals	Recorded capital
Under $5M	8	9.5%	$19.8M
$5M–<$20M	19	22.6%	$216.3M
$20M–<$50M	12	14.3%	$379.6M
$50M–<$100M	7	8.3%	$468.9M
$100M+	21	25.0%	$7.768B
Undisclosed	17	20.2%	-

Which nuclear fusion technology is getting the most money right now?

Tokamak companies currently attract the most fusion capital by a wide margin, with about $4.04 billion across 19 financings.

That is roughly 46% of all quantified funding from only 23% of the deals. Pulsed and magneto-inertial systems come next at about $2.08 billion.

Together, those two groups absorb close to 69% of known capital.

Stellarators and inertial fusion each clear $1 billion, although individual companies still shape those totals heavily. Proxima alone represents roughly 45% of stellarator funding in our window. In inertial fusion, one large financing contributes about 44% of category capital.

Alternative-confinement concepts are much more numerous relative to the money behind them: 16 deals produce only $608.6 million. That part of the market currently has plenty of experimentation and much smaller average financial commitments.

Fusion approach	Deals	Companies	Recorded capital	Capital share
Tokamak Reactors	19	10	$4.038B	45.6%
Pulsed & Magneto-Inertial	13	9	$2.079B	23.5%
Stellarator Reactors	14	8	$1.052B	11.9%
Inertial Fusion Reactors	12	8	$1.023B	11.6%
Alternative Confinement	16	11	$608.6M	6.9%
Fuel & Reactor Components	5	3	$44.5M	0.5%
Control & Diagnostics	3	3	$7.7M	0.09%
Magnet & Power Systems	2	2	Undisclosed	-

Why are some fusion companies suddenly raising hundreds of millions?

The biggest fusion rounds today are paying for machines, factories, magnets and power-plant development rather than another round of basic scientific exploration.

CFS said its $863 million 2025 financing would help complete SPARC and advance work on ARC. Its next $1 billion equity round in 2026 brought in a wider mix of pension, sovereign, infrastructure and industrial capital.

Helion's 2026 Series G reached $500 million after an initial $465 million close. The company said the money was for manufacturing expansion and commercial deployment.

Proxima raised $468 million to push its Alpha stellarator demonstrator forward while expanding its engineering organization. Thea Energy's $100 million round is funding magnet manufacturing and an integrated stellarator system. Focused Energy's $240 million financing brought in investors willing, according to the company, to support the construction path toward a power plant.

The spending around these companies is getting more industrial as well. The Fusion Industry Association's 2026 supply-chain study found that reported supplier spending rose 24% in 2025, while 75% of surveyed suppliers had invested in extra fusion capacity during the previous year.

That's where the giant financing gap comes from. Building a company around promising plasma physics is expensive; building the hardware needed to turn it into electricity is dramatically more expensive.

Are most funded nuclear fusion companies old or new?

Most of the funded nuclear fusion population is surprisingly young, with a median company age of only two years at the time of financing.

The recent formation wave is visible throughout our dataset. Companies founded in 2021 account for 13 financing observations, while 2023 and 2024 contribute 11 each. Companies founded in 2025 already generate 15.

That sits alongside much older names such as TAE, General Fusion, Tokamak Energy and Helion. Those veterans become especially important in larger rounds, but they no longer define the whole private fusion market.

Newer companies including Proxima, Thea, LINEA, Startorus, NovaFusionX and a growing group of Chinese ventures have created another generation of investable fusion companies.

Today's funding market combines two quite different populations: long-running programs with years of engineering behind them and very young teams trying newer architectures, materials or design approaches.

How old are fusion startups before investors write really big checks?

Fusion companies raising more than $50 million are around five years old at the median, compared with one year for companies raising less than $5 million.

The progression by stage also looks sensible. Seed deals happen at a median company age of one year. Series A rises to four years, Series B to five and Series D or later to 13.

Fusion investors can back a young team quite early, especially when the founders come out of established research programs. The heavier financial commitment usually comes after several years of work.

By that point, investors have more to judge: magnet performance, plasma results, subsystem testing, simulation accuracy, manufacturing progress, facility construction and the team's ability to keep hitting milestones.

The age data therefore gives us a clearer view of maturity than the stage labels do.

Where does nuclear fusion funding get much harder?

Nuclear fusion funding gets much harder after Series A, where the visible pipeline drops from 24 Series A deals to only five Series B financings.

We also count 30 Seed rounds, so there is no shortage of companies getting started. The conventional ladder becomes much thinner after the first substantial institutional round.

We should avoid reading the five Series B deals as a literal graduation rate. Fusion companies frequently stop using neat venture labels as their financing becomes more complex, and 15 deals in our research have no reliable conventional stage.

Those unknown-stage rounds contain $3.46 billion, including some of the largest financings in the market.

Still, the broad pattern is hard to miss. Investors are funding plenty of early experiments. The much smaller group that receives serious scale capital has usually produced enough technical evidence to justify a much more expensive machine.

Stage	Deals	Companies	Recorded capital	Median disclosed round
Seed	30	26	$518.3M	$13.8M
Series A	24	19	$2.597B	$33.2M
Series B	5	4	$1.104B	$70.0M
Series C	5	2	$114.3M	$9.9M
Series D+	5	3	$1.055B	$277.5M
Unknown	15	15	$3.463B	$37.4M

Why does nuclear fusion barely have a normal growth-equity stage?

Fusion companies increasingly leave the normal venture ladder behind once their capital needs reach industrial scale.

We record no deal explicitly classified as Growth Equity, even though companies are clearly raising growth-sized amounts. CFS raised $1 billion. Helion's latest round reached $500 million. Proxima raised $468 million.

The labels become messy because the investor base becomes messy too. CFS's latest financing includes institutional, sovereign, infrastructure and industrial money. Public programs also sit beside private capital. Strategic investors can become customers or engineering partners. Some commitments unlock against technical milestones.

The U.S. Department of Energy's current fusion roadmap reflects the same shift. Its Milestone Program now centers on private companies progressing from technical roadmaps toward major integrated experiments and early power-plant concepts, with companies covering most of the underlying project cost themselves.

Later-stage fusion financing already exists. These days, it simply looks less like a conventional growth round and more like a hybrid industrial capital stack.

Is nuclear fusion funding going mainly to new startups or companies that already raised before?

Existing fusion companies currently take most of the money: follow-on financings account for 60 of the 84 deals and about $6.97 billion of recorded capital.

Only 24 deals are first financings in our window. Their median size is $13.8 million, compared with $35.5 million for follow-ons.

The pattern fits how fusion development works. A company can raise an initial round to build the team and prove a subsystem. The next machine usually costs more. If that machine works, the following one can cost much more again.

Proxima's progression is a good example. It raised €20 million in 2024 and then reached a €411 million financing in 2026. Thea moved from a $20 million Series A to a $100 million Series B. Helion, CFS and Startorus have also returned repeatedly for larger amounts.

New-company formation is still healthy. The money, however, increasingly follows companies that have already survived one or more rounds of technical scrutiny.

Who leads nuclear fusion funding right now: the US, China or Europe?

The US currently leads nuclear fusion funding by dollars, while China leads by number of financings.

North America records 23 deals and about $4.86 billion, giving the region roughly 55% of quantified capital. Asia-Pacific generates 47 deals, more than half of all activity, but around $2.80 billion of disclosed capital. Europe has 14 deals and roughly $1.20 billion.

At country level, US companies account for about $4.83 billion across 20 financings. China has 31 deals and around $2.63 billion. Japan has 13 deals but only about $152 million.

The contrast is quite sharp. The US has built the deepest private market for companies raising several hundred million dollars at once. China currently has the widest flow of newly financed companies and approaches. Europe has fewer deals, but Proxima, Focused Energy and Marvel Fusion give it several companies capable of raising substantial rounds.

The regional race looks different depending on what we count. China wins on breadth; the US wins comfortably on disclosed capital.

Are we probably undercounting Chinese fusion funding?

Yes, Chinese nuclear fusion funding is almost certainly understated in dollar terms because many rounds are announced without a precise amount.

Several Chinese transactions are described publicly only as "tens of millions of RMB" or "hundreds of millions of RMB." We keep those deals in the count when they clearly pass our minimum threshold, while leaving their dollar amount undisclosed.

At the same time, China's biggest recorded transaction requires the opposite caution. NeoFusion's approximately $1.31 billion figure comes from an increase in subscribed registered capital from RMB5 billion to RMB14.5 billion. Registered capital can include contributions that differ from cash proceeds received at closing.

The result is a slightly awkward but more defensible picture. Smaller Chinese rounds are probably underrepresented in the aggregate dollar total, while NeoFusion's headline number is less directly comparable with an ordinary preferred-equity financing.

We are therefore more confident in the conclusion that China has exceptional funding breadth than in any claim that its private fusion sector raised exactly $2.63 billion in cash.

Which investors keep coming back to nuclear fusion?

Nuclear fusion still has a surprisingly fragmented lead-investor market, with no firm repeatedly controlling a large share of the rounds we studied.

A lead is publicly identifiable in 54 of 84 financings. Those deals contain 85 distinct lead or co-lead names.

Only seven names appear more than once: East X Ventures, CAS Star, Ant Group, Lowercarbon Capital, 31VENTURES–Global Brain–Growth I, ANRI and CATL. None appears in more than two transactions.

That is unusual for a market where individual rounds can run into hundreds of millions.

Part of the explanation is geography. Chinese fusion companies draw from a different network than US or European companies. Technology also matters: a laser-fusion round, a stellarator round and a Chinese compact-tokamak financing naturally pull different specialists.

The other reason is scale. Once a fusion company needs several hundred million dollars, a standard VC syndicate may no longer be enough. Infrastructure investors, sovereign funds, industrial companies and large institutional pools start appearing beside venture firms.

Why are so many energy and industrial companies investing in fusion?

Strategic investors show up in about 42% of the fusion deals we studied because the companies increasingly need industrial capabilities as much as financial capital.

We identified strategic investors in 35 of 84 financings. The median strategic-backed round is $35.6 million, barely above the $33.2 million median for deals without one. Their importance shows up more clearly in what they bring than in check size.

RWE combines investment with power-plant expertise around companies including Proxima and Focused Energy. Fujikura and Furukawa Electric have direct relevance to superconducting technology. St1 described its investment in Novatron as a long-term industrial partnership that brings commercial, regulatory and energy-market knowledge.

CFS now gives us an even clearer example. Eni, an investor since 2018, signed a power-purchase agreement worth more than $1 billion for electricity from CFS's first ARC plant. Google has committed to 200 MW from the same future plant while also investing in CFS. Hyundai joined CFS's 2026 financing while exploring collaboration around future ARC plants.

Today, the best strategic investor can help a fusion company solve a future customer problem, a supply-chain problem or a plant-engineering problem at the same time.

Why are fusion components and diagnostics raising so little money?

Standalone fusion components and diagnostics currently receive very little startup funding compared with complete reactor developers.

Fuel and reactor-component companies account for only about $44.5 million in our quantified total. Control and diagnostics receive less than $8 million. The magnet and power-systems category contains two financings with undisclosed amounts.

Those numbers look tiny beside the $4.04 billion going into tokamak developers.

The explanation is partly structural. A lot of component development happens inside reactor companies themselves, inside established industrial suppliers, at national laboratories or through public-private research programs. The startup table therefore captures only part of the actual spending.

Recent industry evidence supports that reading. The Fusion Industry Association surveyed 25 fusion companies and 67 suppliers for its 2026 supply-chain report. Reported supply-chain spending reached $538 million in 2025 and was projected to rise to $681 million in 2026. Suppliers highlighted extreme-condition materials, heat management and fuel systems among the longer-term constraints.

As seen above, reactor companies absorb most private funding directly, while a much broader industrial ecosystem is forming around them.

Is nuclear fusion funding really accelerating right now?

Yes, nuclear fusion funding is running at a historically high level right now, although the biggest months are still driven by a few huge transactions.

Across the 33 completed months in our window, the median month contains two deals and about $78.5 million of recorded capital.

The busiest month reaches nine deals. The biggest month by dollars reaches about $1.51 billion from only four financings, led overwhelmingly by CFS's $1 billion round and Proxima's $468 million raise.

The wider sector data confirms that the recent acceleration goes beyond one unusually large month. The Fusion Industry Association reported $4.48 billion raised in the 12 months to July 2026, 69% more than the previous year's survey total.

The mix has also changed. CFS, Helion, Proxima, Focused Energy and Thea all announced major financings recently, while the US Department of Energy's 2026 roadmap now talks explicitly about the infrastructure needed for private fusion companies to scale toward pilot plants and commercial systems.

Fusion funding is clearly hotter these days. The breadth of companies capable of raising the largest checks remains much narrower than the headline growth rate suggests.

Can we really compare every dollar in nuclear fusion funding?

No single nuclear fusion funding total can perfectly compare every transaction, so we preserve the important differences rather than forcing them into false precision.

Pacific Fusion says it has secured more than $900 million, but that capital is tied to predefined milestones. NeoFusion's approximately $1.31 billion comes from subscribed registered capital. Several Chinese deals have no precise disclosed amount at all.

Extensions and extra closes create another problem. Tokamak Energy, Marvel Fusion, Helion and others announced incremental additions to existing rounds during the period. We count an additional close when public evidence shows genuinely new capital, while avoiding a second count of the full round.

Pacific Fusion is particularly useful for understanding how strange these numbers can become. The company genuinely secured more than $900 million of financing support, and that is economically important. Treating the full amount as cash sitting in a bank account on announcement day would tell a different story.

So we use the $8.85 billion total to understand scale, concentration and who can attract capital. For precise cash-comparability across companies, the underlying financing structure still needs to be read deal by deal.

Where does the nuclear fusion funding market hit its real bottleneck?

The real nuclear fusion funding bottleneck today appears when a promising scientific platform has to become an integrated, financeable machine.

Seed funding is active. Series A is active. Young companies continue to enter the market. What gets much harder is assembling enough technical proof, engineering depth and investor confidence to finance the next major hardware step.

Only 19 of 53 companies return for more than one financing in our window. The conventional stage count falls from 24 Series A deals to five Series B deals. Meanwhile, the companies that do break through can jump very quickly into $100 million, $250 million or $500 million financings.

The US Department of Energy's current Milestone Program is built around much the same transition. Its participating private companies are expected to move from technical roadmaps toward major integrated experiments and critical technologies for future fusion power plants, with private capital covering most of the cost.

Investors are willing to fund plenty of fusion ideas. The hard part is becoming one of the relatively few companies that can credibly spend hundreds of millions of dollars on the path toward an actual power plant.

What should we actually take away from the nuclear fusion funding data?

Nuclear fusion has become a serious private-capital market, but its financial depth sits overwhelmingly with a small group of companies. The $8.85 billion total comes from 53 companies, while the top five collect almost 64% of quantified capital.

The typical financing remains much smaller than the headline rounds suggest. A $33.8 million median is a better reference point for most companies than the $132.1 million average.

Capital currently favors reactor developers, especially tokamak and pulsed or magneto-inertial approaches. Companies building integrated machines can move from venture-sized rounds into several hundred million dollars of funding surprisingly quickly once investors believe the technical program is ready.

The market is also young. New fusion companies keep appearing, but repeat financing becomes a powerful filter. Only 19 companies in our window raise more than once.

Industrial and strategic money is now becoming part of the basic financing architecture. Utilities, energy companies, technology buyers and specialist manufacturers are showing up because future fusion plants need customers, materials, engineering and supply chains alongside capital.

The biggest weakness remains the middle of the journey. There are plenty of early financings and a small number of enormous scale rounds. Far fewer companies manage to cross the gap between them.